FY2030 Earnings Forecast for FULC Issued By HC Wainwright

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a report issued on Tuesday, February 24th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of $2.71 for the year. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.31).

FULC has been the subject of a number of other reports. Cantor Fitzgerald boosted their price objective on Fulcrum Therapeutics from $15.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, December 8th. Truist Financial set a $17.00 price target on shares of Fulcrum Therapeutics in a research report on Tuesday. Wall Street Zen cut shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Royal Bank Of Canada upped their target price on shares of Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research report on Monday, December 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Thursday, January 22nd. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.00.

Fulcrum Therapeutics Stock Performance

Fulcrum Therapeutics stock opened at $8.98 on Wednesday. Fulcrum Therapeutics has a one year low of $2.32 and a one year high of $15.74. The stock has a fifty day moving average of $10.73 and a 200 day moving average of $9.48. The stock has a market cap of $486.00 million, a PE ratio of -7.61 and a beta of 3.19.

Insider Transactions at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the sale, the insider owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total value of $178,050.00. Following the transaction, the director owned 469,864 shares of the company’s stock, valued at $5,577,285.68. This trade represents a 3.09% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of large investors have recently bought and sold shares of FULC. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth $30,000. Quarry LP bought a new stake in Fulcrum Therapeutics during the 3rd quarter valued at about $35,000. Meeder Asset Management Inc. bought a new stake in Fulcrum Therapeutics during the 4th quarter valued at about $39,000. Russell Investments Group Ltd. boosted its position in Fulcrum Therapeutics by 4,209.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after buying an additional 9,092 shares during the period. Finally, Farther Finance Advisors LLC grew its stake in Fulcrum Therapeutics by 108.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after acquiring an additional 3,697 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Key Fulcrum Therapeutics News

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Positive Sentiment: Phase 1b PIONEER (20 mg) data showed a large mean absolute HbF increase (from 7.1% to 19.3% at Week 12), improvements in hemolysis and hemoglobin, 7/12 patients reached ≥20% HbF, 58% had zero VOCs during treatment, and no treatment-related SAEs; company plans a potential registration‑enabling trial in H2 2026. Read More.
• Positive Sentiment: HC Wainwright initiated or reiterated bullish modeling with a Buy rating and $25 price target, projecting FY2030 EPS of $2.71 — a materially higher long‑term view than consensus and supportive for upside if clinical development progresses. Read More.
• Positive Sentiment: Stifel commented that the prior share move lower was “overdone,” signaling some sell‑side support for a rebound and reduced downside risk from the recent pullback. Read More.
• Neutral Sentiment: Q4 2025 results: Fulcrum reported (‑$0.31) EPS, in line with consensus; management held a conference call and reiterated development plans — meeting estimates removes an earnings disappointment but leaves focus squarely on clinical progress and the next trials. Read More.
• Neutral Sentiment: Earnings call transcript and investor Q&A are available for detail on runway, timing for a registration‑enabling study and safety/efficacy readouts — items investors will watch for upcoming catalysts. Read More.
• Negative Sentiment: Some headlines noted that the stock still tumbled at points despite the positive trial readout, indicating profit‑taking, short‑term volatility or skepticism about pathway/timing to approval and commercial potential. That volatility can pressure shares until a clear registrational plan and larger study data are available. Read More.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.